TABLE OF CONTENTS

1. INTRODUCTION 33
1.1. OBJECTIVES OF THE STUDY 33
1.2. MARKET DEFINITION 33
1.3. OVERVIEW OF GLOBAL ANTI-SNORING DEVICES AND SNORING SURGERY MARKET 33
1.4. CURRENCY AND PRICING 34
1.5. LIMITATION 34
1.6. MARKETS COVERED 35
2. MARKET SEGMENTATION 38
2.1. MARKETS COVERED 38
2.2. GEOGRAPHIC SCOPE 39
2.3. YEARS CONSIDERED FOR THE STUDY 40
2.4. CURRENCY AND PRICING 40
2.5. RESEARCH METHODOLOGY 41
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.7. SECONDARY SOURCES 45
2.8. ASSUMPTIONS 45
3. MARKET OVERVIEW 46
3.1. DRIVERS 48
3.1.1. RISE IN THE GERIATRIC AS WELL AS OBESE POPULATION 48
3.1.2. MORE OF TECHNOLOGICAL ADVANCEMENT 49
3.1.3. GROWING AWARENESS REGARDING ILL EFFECTS OF SNORING AND RELATED ADVANTAGES 49
3.1.4. INCREASE IN THE CONSUMPTION OF CIGARETTES AND ALCOHOL 49
3.2. RESTRAINTS 50
3.2.1. UNFAVOURABLE REIMBURSEMENT POLICIES 50
3.2.2. HIGH COST OF SURGERIES AND CUSTOM-MADE ORAL DEVICES 50
3.3. OPPORTUNITIES 51
3.3.1. EXISTENCE OF A LARGE UNTREATED POPULACE 51
3.4. CHALLENGES 51
3.4.1. LIMITED EFFICACY AND LACK OF SCIENTIFIC VALIDATION OF THE ANTI-SNORING DEVICES 51
4. EXECUTIVE SUMMARY 52
5. PREMIUM INSIGHTS 55
6. GLOBAL ANTI-SNORING DEVICES AND SURGICAL PROCEDURE MARKET, BY PRODUCT TYPE 58
6.1. OVERVIEW 59
6.2. ORAL APPLIANCES/MOUTHPIECES 61
6.2.1. MANDIBULAR ADVANCEMENT DEVICES (MADS) 63
6.2.1.1. NON-CUSTOM MADS 63
6.2.1.2. CUSTOM-MADE MADS 63
6.2.2. TONGUE-RETAINING DEVICES (TRDS) 63
6.3. NASAL DEVICES 64
6.3.1. EXTERNAL NASAL DILATORS 65
6.3.2. OTHER NASAL DEVICES 65
6.3.2.1. NASAL STENTS 66
6.3.2.2. NASAL CLIPS 66
6.3.2.3. SEPTAL STIMULATORS 67
6.3.2.4. NASAL CONES 67
6.3.2.5. OTHERS 67
6.4. POSITION CONTROL DEVICES 68
6.5. CHIN STRAPS 69
6.6. EPAP THERAPY DEVICES 70
6.7. CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) DEVICES 71
?
7. GLOBAL ANTI-SNORING DEVICES AND SNORING SURGERY MARKET,
BY END-USER 72
7.1. OVERVIEW 73
7.2. HOSPITALS 75
7.3. COMMUNITY HEALTHCARE 76
7.4. SLEEP CLINICS 77
7.5. HOME HEALTHCARE 78
7.6. OTHERS 79
8. GLOBAL ANTI-SNORING DEVICES AND SNORING SURGERY MARKET,
BY TYPE 80
8.1. OVERVIEW 81
8.2. UVULOPALATOPHARYNGOPLASTY (UPPP) 82
8.3. LASER-ASSISTED UVULOPALATOPLASTY (LAUP) 83
8.4. RADIO FREQUENCY ABLATION (SOMNOPLASTY) 84
8.5. PILLAR PROCEDURE 85
8.6. PALATAL STIFFENING PROCEDURES 86
8.7. INJECTION SNOREPLASTY/SCLEROTHERAPY 87
8.8. OTHER ANTI-SNORING SURGICAL PROCEDURES 88
9. GLOBAL ANTI-SNORING DEVICES AND SNORING SURGERY MARKET,
BY DISTRIBUTION CHANNEL 89
9.1. OVERVIEW 90
9.2. RETAIL 92
9.3. DIRECT SALES 93
10. GLOBAL ANTI SNORING DEVICES AND SNORING SURGERY MARKET,
BY GEOGRAPHY 94
10.1. OVERVIEW 95
10.2. NORTH AMERICA 102
10.2.1. U.S. 114
10.2.2. CANADA 119
10.2.3. MEXICO 124
10.3. EUROPE 129
10.3.1. GERMANY 141
10.3.2. FRANCE 146
10.3.3. SWITZERLAND 151
10.3.1. U.K. 156
10.3.2. ITALY 161
10.3.3. NETHERLANDS 166
10.3.4. TURKEY 171
10.3.5. SPAIN 176
10.3.6. BELGIUM 181
10.3.7. RUSSIA 186
10.3.8. REST OF EUROPE 191
10.4. ASIA-PACIFIC 192
10.4.1. JAPAN 204
10.4.2. CHINA 209
10.4.3. SOUTH KOREA 214
10.4.4. INDIA 219
10.4.5. AUSTRALIA 224
10.4.6. SINGAPORE 229
10.4.7. THAILAND 234
10.4.8. MALAYSIA 239
10.4.9. INDONESIA 244
10.4.10. PHILIPPINES 249
10.4.11. REST OF ASIA-PACIFIC 254
10.5. SOUTH AMERICA 255
10.5.1. BRAZIL 266
10.5.2. REST OF SOUTH AMERICA 271
?
10.6. MIDDLE EAST AND AFRICA 272
10.6.1. SOUTH AFRICA 283
10.6.2. REST OF MIDDLE EAST AND AFRICA 288
11. GLOBAL ANTI-SNORING DEVICES AND SNORING SURGERY MARKET, COMPANY LANDSCAPE 289
11.1. COMPANY SHARE ANALYSIS; GLOBAL 289
11.2. COMPANY SHARE ANALYSIS; NORTH AMERICA 290
11.3. COMPANY SHARE ANALYSIS; EUROPE 291
11.4. COMPANY SHARE ANALYSIS; ASIA-PACIFIC 292
12. COMPANY PROFILES 293
12.1. SLEEPING WELL, LLC 293
12.1.1. COMPANY OVERVIEW 293
12.1.2. COMPANY SNAPSHOT 293
12.1.3. PRODUCT PORTFOLIO 293
12.1.4. RECENT DEVELOPMENTS 294
12.2. APNEA SCIENCES CORPORATION 294
12.2.1. COMPANY OVERVIEW 294
12.2.2. COMPANY SNAPSHOT 294
12.2.3. PRODUCT PORTFOLIO 294
12.2.4. RECENT DEVELOPMENTS 295
12.3. THE PURE SLEEP COMPANY 296
12.3.1. COMPANY OVERVIEW 296
12.3.2. COMPANY SNAPSHOT 296
12.3.3. PRODUCT PORTFOLIO 296
12.3.4. RECENT DEVELOPMENTS 296
12.4. KONINKLIJKE PHILIPS N.V. 297
12.4.1. COMPANY OVERVIEW 297
12.4.2. REVENUE ANALYSIS 297
12.4.3. PRODUCT PORTFOLIO 298
12.4.4. RECENT DEVELOPMENTS 299
12.5. SOMNOMED 300
12.5.1. COMPANY OVERVIEW 300
12.5.2. REVENUE ANALYSIS 300
12.5.3. PRODUCT PORTFOLIO 301
12.5.4. RECENT DEVELOPMENTS 301
12.6. FISHER AND PAYKEL HEALTHCARE LIMITED. 302
12.6.1. COMPANY OVERVIEW 302
12.6.2. REVENUE ANALYSIS 302
12.6.3. PRODUCT PORTFOLIO 303
12.6.4. RECENT DEVELOPMENTS 304
12.7. RESMED 305
12.7.1. COMPANY OVERVIEW 305
12.7.2. REVENUE ANALYSIS 305
12.7.3. PRODUCT PORTFOLIO 306
12.7.4. RECENT DEVELOPMENTS 307
12.8. AIRWAY MANAGEMENT INC. 308
12.8.1. COMPANY OVERVIEW 308
12.8.2. COMPANY SNAPSHOT 308
12.8.3. PRODUCT PORTFOLIO 308
12.8.4. RECENT DEVELOPMENTS 308
12.9. THERAVENT, INC. 309
12.9.1. COMPANY OVERVIEW 309
12.9.2. COMPANY SNAPSHOT 309
12.9.3. PRODUCT PORTFOLIO 309
12.9.4. RECENT DEVELOPMENTS 309
?
12.10. TOMED GMBH 310
12.10.1. COMPANY OVERVIEW 310
12.10.2. REVENUE ANALYSIS 310
12.10.3. PRODUCT PORTFOLIO 310
12.10.4. RECENT DEVELOPMENTS 310
12.11. GLAXOSMITHKLINE PLC. 311
12.11.1. COMPANY OVERVIEW 311
12.11.2. REVENUE ANALYSIS 311
12.11.3. PRODUCT PORTFOLIO 312
12.11.4. RECENT DEVELOPMENTS 312
12.12. GE HEALTHCARE 313
12.12.1. COMPANY OVERVIEW 313
12.12.2. REVENUE ANALYSIS 313
12.12.3. PRODUCT PORTFOLIO 314
12.12.4. RECENT DEVELOPMENTS 314
12.13. MEDITAS 315
12.13.1. COMPANY OVERVIEW 315
12.13.2. COMPANY SNAPSHOT 315
12.13.3. PRODUCT PORTFOLIO 315
12.13.4. RECENT DEVELOPMENTS 315
12.14. MEDTRONIC 317
12.14.1. COMPANY OVERVIEW 317
12.14.2. REVENUE ANALYSIS 317
12.14.3. PRODUCT PORTFOLIO 318
12.14.4. RECENT DEVELOPMENTS 318
12.15. ACCUMED CORP. 319
12.15.1. COMPANY OVERVIEW 319
12.15.2. COMPANY SNAPSHOT 319
12.15.3. PRODUCT PORTFOLIO 319
12.15.4. RECENT DEVELOPMENTS 319
12.16. IMTHERA MEDICAL 320
12.16.1. COMPANY OVERVIEW 320
12.16.2. COMPANY SNAPSHOT 320
12.16.3. PRODUCT PORTFOLIO 320
12.16.4. RECENT DEVELOPMENTS 320
13. RELATED REPORTS 321